Marrone Bio Innovations to Present at Upcoming Investor Conferences

DAVIS, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (the “Company” or “MBI”) (NASDAQ: MBII), a leading developer of bio-based products for pest management and plant health, today announced that management will attend several investor conferences in San Francisco and New York throughout September 2019.

Management of Marrone Bio Innovations will host one-on-one meetings throughout the day at the H.C. Wainwright 21st Annual Global Investment Conference and is scheduled to present as follows:

LD Micro SF Summit       Date: Tuesday, September 3, 2019 Speaker: Jim Boyd, Chief Financial Officer Presentation Time: 10:00 a.m. Pacific time           Location: San Francisco, California                 H.C. Wainwright 21st Annual Global Investment Conference       Date: Monday, September 9, 2019 Speaker: Pam Marrone, Chief Executive Officer Presentation Time: 10:00 a.m. Eastern time         Location: Lotte New York Palace Hotel (455 Madison Ave, New York, NY 10022)

Sustainable Investment Forum North America   Date: Wednesday, September 25, 2019 Attendee: Pam Marrone, Chief Executive Officer Format: Attendee only (No presentation)             Location: Crowne Plaza Hotel (1605 Broadway, New York, NY 10019)

Diamond Equity Research Emerging Growth Invitational Date: Wednesday, September 25, 2019 Speaker: Pam Marrone, Chief Executive Officer Event Time: 6:00 – 9:30 p.m. Eastern time Location: The Cornell Club (6 East 44th Street, New York, NY 10017)

Conference participation is by invitation only and registration is mandatory. For more information or to schedule a one-on-one meeting, please contact your conference representative.

About Marrone Bio Innovations                Marrone Bio Innovations Inc. (NASDAQ: MBII) is a growth-oriented company leading the movement to more a sustainable world through the discovery, development and sale of innovative biological products for crop protection, plant health and waterway systems treatment that help customers operate more sustainably while increasing their return on investment. MBI has screened over 18,000 microorganisms and 350 plant extracts, leveraging its in-depth knowledge of plant and soil microbiomes enhanced by advanced molecular technologies and natural product chemistry to rapidly develop seven product lines. Supported by a robust portfolio of over 400 issued and pending patents, MBI’s currently available commercial products are Regalia®, Stargus®, Grandevo®, Venerate®, Majestene®, Haven® and Amplitude®, Zelto® and Zequanox®, with a breakthrough bioherbicide and biofumigant in the company’s product pipeline.

Learn more about Marrone Bio Innovations at www.marronebio.com. Follow us on social media: Twitter, LinkedIn and Instagram.

Marrone Bio Innovations Contacts:         Pam Marrone, CEO and Founder               Telephone: +1 (530) 750-2800     Email: [email protected]   

Investor Relations:          Greg Falesnik     Managing Director           MZ Group – MZ North America  Main: 949-385-6449         [email protected]           www.mzgroup.us           

Source: Marrone Bio Innovations

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Rocket Lab Satellite Platforms Built for MDA Space Successfully Reach Orbit, Supporting Globalstar Direct-to-Device Communications Services
• Globalstar Confirms Successful Launch of All 8 HIBLEO-4 Replacement Satellites
• Crypto News Today Is All Fear and Delays but the Smartest Wallets Already Found Their Entry